Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Financings Neutral

MedX Announces Final Closing of Non-brokered Private Placement

MedX Secures Runway with Debt Refinancing Amidst Dilution Concerns and Modest Cash Injection

By The Northwire Desk — AI Analysis May 15, 2026 · 19:40 MDX · 0.05 Medx Health Corp.
Executive Summary
  • MedX Health Corp. announced the final closing of its Series IV Convertible Loan Notes private placement on May 15, 2026.
  • Total notes issued amount to $2,800,000 face value.
  • Breakdown includes $2,400,000 from surrender/conversion of existing Series I notes and $400,000 in new cash subscriptions ($300k initial + $100k subsequent).
  • Proceeds designated for SIAscopy® technology development on the DermSecure® platform, occupational health market expansion, and general corporate purposes.
  • Terms include 6% annual interest payable quarterly, maturing December 31, 2028.
  • Conversion terms allow holders to convert notes into units at $0.10 per unit (1 share + ½ warrant).
  • Warrants are exercisable for one common share at $0.125 until maturity.
Material Impact
  • The financing was announced in February 2026 and extended in March, making the final closing an expected event rather than a surprise catalyst.
  • The actual new cash raised is only $400,000, which is modest for a company developing technology and expanding into new markets.
  • The majority of the funding ($2.4M) is a debt swap (Series I to Series IV), primarily extending maturity and refinancing existing obligations rather than providing significant growth capital.
  • Conversion price of $0.10 is double the current trading price of $0.05, indicating potential dilution risk if holders convert, though currently out-of-the-money.
  • The event prevents immediate default on Series I notes but does not materially alter the company's long-term valuation or operational trajectory in isolation.
MDX · Price
Company Overview
  • Flagship Project: SIAscopy® technology on the DermSecure® telemedicine platform.
  • Technology: AI-driven skin analysis using an image database of ~85,000 clinically reviewed images (blood, melanin, collagen components).
  • Divisions: Includes Photobiomodulation division with products LumaVet (veterinary) and Oralase (dental).
  • Operations: Serves Contract Research Organizations (CROs) and beauty brands; released from exclusive P&G licensing to pursue direct opportunities.
Read the original news release →

More from Medx Health Corp.

Jun 25, 2026 · 23:52

MedX Health Launches SkinSecure SaaS to Target CRO Market, But Liquidity Crisis and Going Concern Risks Dominate

Other Mar 16, 2026 · 07:00

MedX Announces Application for Extension of Non-Brokered Private Placement

Financings Feb 27, 2026 · 11:44

MedX Health closes $2.7-million private placement

Financings Feb 27, 2026 · 07:00

MedX Announces $2,700,000 Initial Closing of Non-Brokered Private Placement of Series IV Convertible Loan Notes

Financings Feb 02, 2026 · 21:05

MedX Health arranges $5-million note financing

Financings Feb 02, 2026 · 17:01

MedX Announces Non-Brokered Private Placement of Series IV Convertible Loan Notes

Financings